Rasburicase

被引：12

作者：

Easton J. ^{[1
]}

Noble S. ^{[1
]}

Jarvis B. ^{[1
]}

机构：

[1] Adis International Limited, Auckland 10

来源：

Paediatric Drugs | 2001年 / 3卷 / 6期

关键词：

Uric Acid; Allopurinol; Uric Acid Level; Allantoin; Noncomparative Study;

D O I：

10.2165/00128072-200103060-00004

中图分类号：

学科分类号：

摘要：

Rasburicase (recombinant urate oxidase) is a uricolytic agent which has been developed for the prevention and treatment of chemotherapy-induced hyperuricaemia at a dosage of 0.15 or 0.2 mg/kg/day in patients with haematological malignancies. Significant reductions from baseline in plasma uric acid levels were seen in 3 noncomparative and 1 randomised comparative trial of rasburicase in patients with, or at high risk of, hyperuricaemia. A multicentre, nonblind, randomised trial found that patients who received intravenous rasburicase 0.2 mg/kg/day experienced an average 2.6-fold less exposure to uric acid than those who received oral allopurinol 10 mg/kg/day. There was no evidence of renal insufficiency in 3 noncomparative trials which monitored creatinine levels to assess renal function during chemotherapy and rasburicase treatment. Rasburicase was generally well tolerated in clinical trials, with skin rashes reported in ≈2% of patients. Bronchospasm, nausea and vomiting, and haemolysis occurred less frequently. In all cases the patients had also received chemotherapy prior to the adverse event.

引用

页码：433 / 437

页数：4

共 13 条

[1]

Dussossoy D., Py M.L., Pastor G., Et al., Development of a two-site immunoassay of recombinant urate oxidase (SR 29142) and its use for determination of pharmacokinetic parameters in rats and baboons, J Pharm Sci, 85, pp. 955-959, (1996)

[2]

Pui C.-H., Mahmoud H.H., Wiley J.M., Et al., Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma, J Clin Oncol, 19, pp. 697-704, (2001)

[3]

Pui C.-H., Relling M.V., Lascombes F., Et al., Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies, Leukemia, 11, 11, pp. 1813-1816, (1997)

[4]

Mahmoud H.H., Leverger G., Patte C., Et al., Advances in the management of malignancy-associated hyperuricaemia, Br J Cancer, 4, 77 SUPPL., pp. 18-20, (1998)

[5]

Landman-Parker J., Auvrignon-Decubber A., Tourniaire B., Et al., Preliminary results of a new generation urate oxidase enzyme, SR 29142, for prevention and treatment of hyper-uricemia related to tumor lysis syndrome in childhood acute leukemia, Med Pediatr Oncol, 29, (1997)

[6]

Schaison G., Leverger G., Patte C., Et al., Administration of recombinant urate oxidase SR29142 for prevention of hyperuricemia in 54 patients with acute leukemias (AL) or non-Hodgkin lymphomas, 88th Annual Meeting of the American Association of Cancer Research, 38, (1997)

[7]

Mahmoud H.H., Czerniak R., Auvrignon A., Et al., Pharmacokinetics of recombinant urate oxidase SR29142 and anti-SR29142 antibodies in patients with cancer, Med Pediatr Oncol, 31, (1998)

[8]

Lascombes F., Sommelet D., Gebhard F., Et al., High efficacy of recombinant urate oxidase in prevention of renal failure related to tumor lysis syndrome (TLS), Blood, 92, SUPPL. 1 PART 2, (1998)

[9]

Pui C.-H., Wiley J.M., Woods G.M., Et al., Recombinant urate oxidase corrects hyperuricemia in patients treated for leukemia or lymphoma, Blood, 92, SUPPL. 1 PART 1, (1998)

[10]

Goldman S.C., Holcenberg J.S., Finklestein J.Z., Et al., A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk of tumor lysis, Blood, 97, 10, pp. 2998-3003, (2001)

← 1 2 →